English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/193968
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Glucocorticoids and Glucocorticoid-Induced-Leucine-Zipper (GILZ) in Psoriasis

AuthorsSevilla, Lisa M. ; Pérez, Paloma
KeywordsGlucocorticoid-induced-leucine-zipper (GILZ/TSC22D3)
Glucocorticoids (GCs)
Immune cells
Keratinocytes
Psoriasis
Signaling
Skin inflammation
Issue Date13-Sep-2019
PublisherFrontiers Media
CitationFrontiers in Immunology 10:2220. (2019)
AbstractPsoriasis is a prevalent chronic inflammatory human disease initiated by impaired function of immune cells and epidermal keratinocytes, resulting in increased cytokine production and hyperproliferation, leading to skin lesions. Overproduction of Th1- and Th17-cytokines including interferon (IFN)-γ, tumor necrosis factor (TNF)-α, interleukin (IL)-23, IL-17, and IL-22, is a major driver of the disease. Glucocorticoids (GCs) represent the mainstay protocol for treating psoriasis as they modulate epidermal differentiation and are potent anti-inflammatory compounds. The development of safer GC-based therapies is a high priority due to potentially severe adverse effects associated with prolonged GC use. Specific efforts have focused on downstream anti-inflammatory effectors of GC-signaling such as GC-Induced-Leucine-Zipper (GILZ), which suppresses Th17 responses and antagonizes multiple pro-inflammatory signaling pathways involved in psoriasis, including AP-1, NF-κB, STAT3, and ROR-γt. Here we review evidence regarding defective GC signaling, GC receptor (GR) function, and GILZ in psoriasis. We discuss seemingly contradicting data on the loss- and gain-of-function of GILZ in the imiquimod-induced mouse model of psoriasis. We also present potential therapeutic strategies aimed to restore GC-related pathways.
DescriptionArtículo con 9 páginas y 2 figuras.
Publisher version (URL)http://dx.doi.org/10.3389/fimmu.2019.02220
URIhttp://hdl.handle.net/10261/193968
DOI10.3389/fimmu.2019.02220
E-ISSN1664-3224
Appears in Collections:(IBV) Artículos
Files in This Item:
File Description SizeFormat 
2019 Front Immunol 10-2220.pdf815,45 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.